NFKBIB Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q15653 |
---|---|
Clone Names | 100430111 |
Gene ID | 4793 |
---|---|
Other Names | NF-kappa-B inhibitor beta, NF-kappa-BIB, I-kappa-B-beta, IkB-B, IkB-beta, IkappaBbeta, Thyroid receptor-interacting protein 9, TR-interacting protein 9, TRIP-9, NFKBIB, IKBB, TRIP9 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13780b was selected from the C-term region of NFKBIB. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | NFKBIB |
---|---|
Synonyms | IKBB, TRIP9 |
Function | Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further NFKBIA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation. |
Cellular Location | Cytoplasm. Nucleus. |
Tissue Location | Expressed in all tissues examined. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL(MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form theNFKB complex. The NFKB complex is inhibited by I-kappa-B proteins(NFKBIA, MIM 164008, or NFKBIB), which inactivate NF-kappa-B bytrapping it in the cytoplasm. Phosphorylation of serine residues onthe I-kappa-B proteins by kinases (IKBKA, MIM 600664 or IKBKB, MIM603258) marks them for destruction via the ubiquitination pathway,thereby allowing activation of the NF-kappa-B complex. ActivatedNFKB complex translocates into the nucleus and binds DNA atkappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or Gpurine; and Y is a C or T pyrimidine).
References
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Potter, C., et al. Ann. Rheum. Dis. 69(7):1315-1320(2010)Segat, L., et al. Vaccine 28(10):2201-2206(2010)McGeachie, M., et al. Circulation 120(24):2448-2454(2009)Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.